Business
Aethlon Medical to Release Second Quarter Financial Results and Host Conference Call on November 14, 2023
SAN DIEGO, Nov. 6, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and
About this update from Aethlon Medical, Inc.
[{"type":"text","content":"SAN DIEGO, Nov. 6, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening viral infections and for use in organ transplantation, today announced that it will issue financial results for its second quarter ended September 30, 2023, at 4:15 p.m. ET on Tuesday, November 14, 2023.\n\n \n \n \n \n \n \n\n \nManagement will host a conference call on Tuesday, November 14, 2023 at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session.\nInterested parties can register for the conference by navigating to https://dpregister.com/sreg/10184181/fafb1d3fee. Please note that registered participants will receive their dial in number upon registration.\nInterested parties without internet access or unable to pre-register may dial in by calling:\nPARTICIPANT DIAL IN (TOLL FREE): 1-844-836-8741PARTICIPANT INTERNATIONAL DIAL IN: 1-412-317-5442\nAll callers should ask for the Aethlon Medical, Inc. conference call.\nA replay of the call will be available approximately one hour after the end of the call through December 14, 2023. The replay can be accessed via Aethlon Medical's website or by dialing 1-877-344-7529 (domestic) or 1-412-317-0088 (international) or Canada toll free at 1-855-669-9658. The replay conference ID number is 2507359.\nAbout Aethlon and the Hemopurifier®Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and harmful exosomes from blood utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the ...